Evidence map›Paper›PMID 32188490›Full record

ArticleGenome medicine2020

Clinical and molecular characterization of virus-positive and virus-negative Merkel cell carcinoma.

Gabriel J Starrett, Manisha Thakuria, Tianqi Chen, Christina Marcelus, Jingwei Cheng, Jason Nomburg, Aaron R Thorner, Michael K Slevin, Winslow Powers, Robert T Burns and 7 more

Open access · goldAbstract read
In one paragraph

Article in Genome medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 115 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Gabriel J StarrettLaboratory of Cellular Oncology, CCR, NCI, NIH, Bethesda, MD, USA.
Manisha ThakuriaDepartment of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Tianqi ChenDepartment of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Christina MarcelusDepartment of Medical Oncology, Dana-Farber Cancer Institute, Mayer 440, 450 Brookline Avenue, Boston, MA, 02215, USA.
Jingwei ChengDepartment of Medical Oncology, Dana-Farber Cancer Institute, Mayer 440, 450 Brookline Avenue, Boston, MA, 02215, USA.
Jason NomburgDepartment of Medical Oncology, Dana-Farber Cancer Institute, Mayer 440, 450 Brookline Avenue, Boston, MA, 02215, USA.
Aaron R ThornerCenter for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, USA.
Michael K SlevinCenter for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, USA.
Winslow PowersCenter for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, USA.
Robert T BurnsCenter for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, USA.
Caitlin PerryDepartment of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, MA, USA.
Adriano PirisDepartment of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Frank C KuoDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Guilherme RabinowitsMerkel Cell Carcinoma Center of Excellence, Dana-Farber/Brigham Cancer Center, Boston, MA, USA.
Anita Giobbie-HurderDepartment of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Laura E MacConaillCenter for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, USA.
James A DeCaprioMerkel Cell Carcinoma Center of Excellence, Dana-Farber/Brigham Cancer Center, Boston, MA, USA. James_DeCaprio@dfci.harvard.edu.
Dana-Farber Cancer Institute · USBrigham and Women's Hospital · USCenter for Cancer Research · USDana-Farber Brigham Cancer Center · US

Funding

PROJECT 4: Interrogating PP2A Signaling in Human CancersP01CA203655 · NCI · DANA-FARBER CANCER INST · PI DECAPRIO, JAMES A. · 2017 to 2021
$8.0M
The DREAM B-Myb-MuvB complex controls sensitivity to DNA replication activators and inhibitorsR35CA232128 · NCI · DANA-FARBER CANCER INST · PI DECAPRIO, JAMES A. · 2019 to 2025
$7.2M
Biology of Virus-associated CancersZIABC011894 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STARRETT, GABRIEL · 2019 to 2025
$5.4M
RB-RELATED PROTEINS IN SV4OT AND E1A TRANSFORMATIONR01CA063113 · NCI · DANA-FARBER CANCER INSTITUTE · PI DECAPRIO, JAMES A. · 1994 to 2018
$5.0M
Transforming Mechanisms of Merkel Cell Polyoma VirusR01CA173023 · NCI · DANA-FARBER CANCER INST · PI DECAPRIO, JAMES A. · 2013 to 2019
$2.3M
Validation of EP400 downstream effectors and potential therapeutic targets in Merkel cell carcinomaR50CA243777 · NCI · DANA-FARBER CANCER INST · PI CHENG, JINGWEI · 2019 to 2020
$328k
NCI NIH HHS P01 CA203655NCI NIH HHS R01 CA063113NCI NIH HHS R01 CA173023NCI NIH HHS R35 CA232128NCI NIH HHS R50 CA243777NIH HHS P01CA203655NIH HHS R01CA173023NIH HHS R01CA63113NIH HHS R35CA232128
6 · The paper itself

Abstract

backgroundMerkel cell carcinoma (MCC) is a highly aggressive neuroendocrine carcinoma of the skin caused by either the integration of Merkel cell polyomavirus (MCPyV) and expression of viral T antigens or by ultraviolet-induced damage to the tumor genome from excessive sunlight exposure. An increasing number of deep sequencing studies of MCC have identified significant differences between the number and types of point mutations, copy number alterations, and structural variants between virus-positive and virus-negative tumors. However, it has been challenging to reliably distinguish between virus positive and UV damaged MCC.

methodsIn this study, we assembled a cohort of 71 MCC patients and performed deep sequencing with OncoPanel, a clinically implemented, next-generation sequencing assay targeting over 400 cancer-associated genes. To improve the accuracy and sensitivity for virus detection compared to traditional PCR and IHC methods, we developed a hybrid capture baitset against the entire MCPyV genome and software to detect integration sites and structure.

resultsSequencing from this approach revealed distinct integration junctions in the tumor genome and generated assemblies that strongly support a model of microhomology-initiated hybrid, virus-host, circular DNA intermediate that promotes focal amplification of host and viral DNA. Using the clear delineation between virus-positive and virus-negative tumors from this method, we identified recurrent somatic alterations common across MCC and alterations specific to each class of tumor, associated with differences in overall survival. Finally, comparing the molecular and clinical data from these patients revealed a surprising association of immunosuppression with virus-negative MCC and significantly shortened overall survival.

conclusionsThese results demonstrate the value of high-confidence virus detection for identifying molecular mechanisms of UV and viral oncogenesis in MCC. Furthermore, integrating these data with clinical data revealed features that could impact patient outcome and improve our understanding of MCC risk factors.

Indexed as

MutationAdolescentAdultAgedAged, 80 and overCarcinoma, Merkel CellChildDNA, NeoplasmDNA, ViralFemaleGenetic TestingHumansMaleMiddle AgedPolyomavirusPolyomavirus InfectionsDNA, NeoplasmDNA, ViralCancer genomicsIntegrationMutagenesisPolyomavirusSomatic variants

Identifiers

PMID32188490
PMCPMC7081548
OpenAlexW3012874801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.